Share on StockTwits

Equities researchers at Canaccord Genuity initiated coverage on shares of Trivascular Technologies (NASDAQ:TRIV) in a research report issued on Monday, TheFlyOnTheWall.com reports. The firm set a “buy” rating and a $20.00 price target on the stock. Canaccord Genuity’s target price would indicate a potential upside of 42.25% from the company’s current price.

Trivascular Technologies (NASDAQ:TRIV) opened at 14.06 on Monday. Trivascular Technologies has a 52 week low of $11.15 and a 52 week high of $16.00. The stock has a 50-day moving average of $13.46 and a 200-day moving average of $13.46. The company’s market cap is $271.8 million.

Trivascular Technologies (NASDAQ:TRIV) last announced its earnings results on Wednesday, May 14th. The company reported ($1.17) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($1.10) by $0.07. The company had revenue of $7.00 million for the quarter, compared to the consensus estimate of $6.90 million. During the same quarter in the prior year, the company posted ($1.17) earnings per share. The company’s quarterly revenue was up 141.4% on a year-over-year basis. On average, analysts predict that Trivascular Technologies will post $-2.75 earnings per share for the current fiscal year.

Other equities research analysts have also recently issued reports about the stock. Analysts at JPMorgan Chase & Co. initiated coverage on shares of Trivascular Technologies in a research note on Monday, May 12th. They set an “overweight” rating and a $18.00 price target on the stock. Separately, analysts at Stifel Nicolaus initiated coverage on shares of Trivascular Technologies in a research note on Monday, May 12th. They set a “buy” rating and a $17.00 price target on the stock. They noted that the move was a valuation call. Finally, analysts at Credit Suisse initiated coverage on shares of Trivascular Technologies in a research note on Monday, May 12th. They set an “outperform” rating and a $17.00 price target on the stock.

Trivascular Technologies, Inc is a medical device company. The Company is developing and commercializing technologies to significantly advance minimally invasive treatment of abdominal aortic aneurysms (NASDAQ:TRIV).

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.